Current News
2025
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2024
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2023
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2022
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2021
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2020
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2019
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2018
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2016
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2015
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2014
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2013
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2012
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2011
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
2010
Lipoxen client win
17 November 2010
Lipoxen (AIM: LPX.L), the leading UK biopharmaceutical company providing specialist delivery solutions to improve the efficacy and performance of drugs and vaccines, has appointed Walbrook PR Ltd as its financial PR and IR advisor.
Walbrook's brief is to advise Lipoxen on its communications with the financial media, sector analysts, private client brokers and other investors.
Lipoxen works with some of the world's leading biotechnology and pharmaceutical companies to identify product candidates with significant market potential, co-develop new product candidates and improve protein, vaccine and anti-cancer drug performance.
.jpg "Fusion Antibodies - Landscape (Trimmed)")
.png "MyHealthChecked PLC_Logo_2 Line_Colour_Red_RGB_AW (003)"){kind=logo}
